Jubilant Ingrevia Limited completes acquisition of 100% stake in Remidex Pharma
Jubilant Ingrevia · Chemicals & Petrochemicals
Key highlights
- Company entered into Share Purchase Agreement with Remidex Pharma Private Limited for full acquisition
- Acquisition completion was on March 30, 2026 at 6:05 pm IST
- Details of the transaction were previously disclosed on March 13, 2026 and updated filings are on the company website
Why it's rated notable: The filing confirms completion of the acquisition of a 100% stake in Remidex but states no consideration amount, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Jubilant Ingrevia
- Acquisition / mergerNotableJubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
- NHC Foods approves Sept 2026 quarter results, buys 99.98% of Sachmaas Foods
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.